Jupiter Topco LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 321,072 shares of the company's stock, valued at approximately $90,857,000. Jupiter Topco LLC owned about 0.17% of Cencora at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in COR. BlackRock Inc. acquired a new position in shares of Cencora during the 2nd quarter valued at $5,154,136,000. State Street Corp increased its stake in Cencora by 1.3% in the 4th quarter. State Street Corp now owns 9,305,507 shares of the company's stock worth $3,142,935,000 after purchasing an additional 115,191 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Cencora by 160.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company's stock worth $2,262,956,000 after buying an additional 4,123,795 shares during the period. Geode Capital Management LLC raised its holdings in Cencora by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company's stock worth $1,843,268,000 after buying an additional 169,055 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Cencora by 6.5% during the fourth quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company's stock valued at $1,682,859,000 after buying an additional 304,760 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.
Wall Street Analysts Forecast Growth
COR has been the topic of several analyst reports. Royal Bank Of Canada started coverage on shares of Cencora in a research report on Wednesday, August 19th. They issued a "sector perform" rating and a $330.00 target price on the stock. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Barclays decreased their target price on Cencora from $425.00 to $350.00 and set an "overweight" rating for the company in a research report on Wednesday, June 10th. Robert W. Baird set a $370.00 price target on Cencora in a report on Thursday, August 6th. Finally, Bank of America upped their price target on Cencora from $280.00 to $285.00 and gave the company a "neutral" rating in a research report on Wednesday, June 24th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $370.85.
Read Our Latest Stock Report on Cencora
Insider Buying and Selling
In other Cencora news, EVP Elizabeth S. Campbell sold 11,300 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lauren M. Tyler purchased 550 shares of the company's stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the transaction, the director owned 4,359 shares of the company's stock, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.38% of the stock is currently owned by company insiders.
Cencora Price Performance
COR opened at $327.94 on Thursday. The stock has a fifty day moving average price of $305.39 and a 200 day moving average price of $311.07. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market cap of $62.58 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 1.88 and a beta of 0.57.
Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company had revenue of $84.75 billion during the quarter, compared to the consensus estimate of $84.31 billion. During the same period in the previous year, the firm posted $4.00 earnings per share. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. Analysts forecast that Cencora, Inc. will post 17.87 EPS for the current fiscal year.
Cencora Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, August 14th. Cencora's dividend payout ratio (DPR) is presently 17.83%.
Cencora declared that its board has initiated a share repurchase plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's management believes its stock is undervalued.
About Cencora
(
Free Report)
Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
